8-K current report · filed Sep 15, 2026

Scholar Rock Holding Corp (SRRK) 8-K Current Report: September 15, 2026

Item 7.01SRRK overview

Short answer

Scholar Rock Holding Corp (SRRK) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). FDA approved ISEMBYLD for spinal muscular atrophy patients aged 2 and older receiving SMN2-targeted treatment.

Scholar Rock Holding Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • FDA approved ISEMBYLD for spinal muscular atrophy patients aged 2 and older receiving SMN2-targeted treatment
  • Management corrected prior statement: FDA requires a pregnancy safety study covering complications and birth outcomes
  • FDA also requested 15-day alert reporting for domestic and foreign fracture cases
  • Post-marketing commitments add safety-monitoring obligations and potential compliance costs after approval

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Scholar Rock Holding Corp 8-K filings

Get the next SRRK 8-K as it lands

Follow SRRK for push alerts, or ask the research agent what this filing means.